切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2015, Vol. 11 ›› Issue (05) : 584 -588. doi: 10.3877/cma.j.issn.1673-5250.2015.05.007

所属专题： 文献；

论著

不同促性腺激素进行控制性超促排卵的临床结局比较
黄夏曼1, 顾方乐1, 吕芳1, 潘宇1, 张晓梅1,*,*()   
  1. 1. 225001　扬州大学临床医学院生殖医学中心
  • 收稿日期:2015-06-12 修回日期:2015-08-09 出版日期:2015-10-01
  • 通信作者: 张晓梅

Comparison of clinical outcomes of controlled ovarian stimulation with different gonadotropin

Xiaman Huang1, Fangle Gu1, Fang Lyu1, Yu Pan1, Xiaomei Zhang1()   

  1. 1. Reproductive Medicine Center of Clinical Medical School of Yangzhou University, Yangzhou 225001, Jiangsu Province, China
  • Received:2015-06-12 Revised:2015-08-09 Published:2015-10-01
  • Corresponding author: Xiaomei Zhang
  • About author:
    Corresponding author: Zhang Xiaomei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

黄夏曼, 顾方乐, 吕芳, 潘宇, 张晓梅. 不同促性腺激素进行控制性超促排卵的临床结局比较[J/OL]. 中华妇幼临床医学杂志(电子版), 2015, 11(05): 584-588.

Xiaman Huang, Fangle Gu, Fang Lyu, Yu Pan, Xiaomei Zhang. Comparison of clinical outcomes of controlled ovarian stimulation with different gonadotropin[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(05): 584-588.

目的

探讨不同促性腺激素(Gn)[重组人促卵泡激素(rFSH)与尿源性卵泡刺激素(uFSH)]进行控制性超促排卵(COH)临床结局的差异。

方法

选择2011年1月至2013年12月于扬州大学临床医学院生殖医学中心进行体外受精/卵胞浆内单精子注射-胚胎移植(IVF/ICSI-ET)助孕的396例患者共计428个周期为研究对象。按使用Gn药物的不同，将其分为rFSH组(253个周期)和uFSH组(175个周期)。比较两组患者一般情况、Gn用量、Gn使用天数、获卵数、优质卵泡数、种植率、不良结局发生率、妊娠率、活产率、自然流产率、多胎妊娠率以及卵巢刺激综合征(OHSS)发生率。两组患者年龄、体质指数(BMI)及不孕年限等一般临床病历资料比较，差异均无统计学意义(P>0.05)。

结果

①两组患者不孕因素中男方因素比较，差异有统计学意义(χ2＝10.322；P<0.05)。而两组患者年龄、BMI、不孕年限、不孕类型、不孕原因中子宫内膜异位症、多囊卵巢综合征(PCOS)、不明原因不孕等方面比较，差异均无统计学意义(P>0.05)。②rFSH组和uFSH组Gn使用天数[(9.4±1.7)d vs (9.8±2.2) d]、Gn用量[(1 883.5±532.3) U vs (2 277.1±694.2) U]、获卵数[(12.3±6.1)个vs (10.1±5.4)个]、优质卵泡数[(9.1±5.2)个vs (7.8±4.9)个]、不良周期结局(9.1% vs 25.1%)、注射hCG日孕酮水平[(3.7±2.1)U/L vs (2.8±1.6) U/L]、活产率(69.7% vs 50.0%)比较，差异均有统计学意义(χ2＝2.154，6.227，3.564，2.373，20.187，3.488，0.033；P<0.05)。

结论

rFSH所需Gn总剂量少，刺激周期短，改善了卵母细胞的数量和质量，并能减少不良结局发生率，最终获得更高的活产率。

关键词: 排卵诱导, 卵泡刺激素，人, 尿促卵泡素, 体外受精, 胚胎移植
Objective

To investigate differences in clinical outcomes of ovulation by different gonadotropin (Gn), including recombinant human follicle stimulating hormone (rFSH) and urinary FSH (uFSH).

Methods

A total of 396 cases of patients undergoing in vitro fertilization/intra-cytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET)in Reproductive Medicine Center of Clinical Medical School of Yangzhou University from January 2011 to December 2013, a total of 428 cycles were collected as the research object. According to different types of Gn, the patient were divided into rFSH group (253 cycles) and uFSH group (175 cycles). General data, Gn dosage, number of Gn days, number of oocytes, the number of high-quality eggs, implantation rate, the incidence of adverse outcomes, pregnancy, live birth rate, abortion rate, multiple pregnancies and the incidence of ovarian hyperstimulation syndrome(OHSS) between two groups were compared. There were no significant differences in age, body mass index (BMI), and other clinical data between two groups (P>0.05).

Results

①The comparison between two groups of patients infertility factors, the difference of male factor was statistically significant(χ2=10.322, P<0.05). There were no statistically significant difference between two groups in age, BMI, duration of infertility, infertility type, causes of infertility in endometriosis, polycystic ovary syndrome (PCOS), unexplained infertility, etc. (P>0.05). ②The difference in number of Gn days [(9.4±1.7) d vs (9.8±2.2) d], Gn dosage [(1 883.5±532.3) U vs (2 277.1±694.2) U], the number of oocytes [(12.3±6.1) vs (10.1±5.4)], the number of high-quality eggs [(9.1±5.2) vs (7.8±4.9)], the incidence of adverse outcomes (9.1% vs 25.1%), progesterone level of hCG day [(3.7±2.1) U / L vs (2.8±1.6) U / L], live birth rate (69.7% vs 50.0%) between two groups were statistically significant (χ2=2.154, 6.227, 3.564, 2.373, 20.187, 3.488, 0.033; P<0.05).

Conclusions

Using rFSH, the total dose of Gn is less required and period to stimulate is short, it also improvs the quantity and quality of oocytes, at the same time, it can reduce the rate of adverse outcomes, and get high live birth rate.

Key words: Ovulation induction, Follicle stimulating hormone, human, Urofollitropin, Fertilization in vitro, Embryo transfer
表1 两组患者一般情况比较(±s)
组别 周期(个) 年龄(岁) BMI (kg/m2) 不孕年限(年) 不孕类型[个(%)] 不孕因素[个(%)]
原发不孕 继发不孕 盆腔及输卵管因素 子宫内膜异位症 PCOS 男方因素 不明原因 其他
rFSH组 253 29.5±2.9 21.9±3.2 4.2±3.1 156(61.7) 97(38.3) 134(52.9) 16(6.3) 30(11.9) 111(43.9) 6(2.4) 8(3.2)
uFSH组 175 29.8±2.9 21.9±2.5 4.5±3.2 112(64.0) 63(36.0) 106(60.6) 15(8.6) 16 (9.1) 50(28.6) 5(2.9) 5(2.9)
χ2值/t值   0.490 0.639 0.546 0.242 0.242 2.430 0.778 0.795 10.322 0.097 0.033
P值   0.310 0.969 0.589 0.623 0.623 0.119 0.378 0.373 0.001 0.755 0.857
表2 两组不良周期结局比较[个(%)]
组别 周期 未取卵 未取到卵 未授精 未受精 无可移植胚胎
rFSH组 23 4(17.4) 0(0.0) 1(4.4) 11(47.8) 7(30.4)
uFSH组 44 19(43.2) 1(2.3) 1(2.3) 4 (9.1) 19(43.2)
χ2值 20.187
P值 0.000
表3 两组促排卵情况比较(±s)
组别 周期(个) 注射hCG日 Gn使用天数(d) Gn用量(U) 获卵数(个) 优质卵泡数(个)  
子宫内膜厚度(mm) 雌二醇(pmol/L) LH (U/L) 孕酮(U/L)
rFSH组 253 10.7±2.2 7 875.9±4 650.5 1.4±1.2 3.7±2.1 9.4±1.7 1 883.5±532.3 12.3±6.1 9.1±5.2  
uFSH组 175 10.5±2.6 8 114.5±4 226.8 1.2±0.8 2.8±1.6 9.8±2.2 2 277.1±694.2 10.1±5.4 7.8±4.9  
t值   0.590 0.369 1.604 3.488 2.154 6.227 3.564 2.373  
P值   0.556 0.713 0.110 0.001 0.039 0.000 0.001 0.018  
表4 两组临床结局比较[个(%)]
组别 周期 种植率 妊娠率 活产率 自然流产率 多胎妊娠率 OHSS发生率
rFSH组 230 93(21.2) 89(38.7) 62(69.7) 13(14.6) 17(19.1) 4(1.7)
uFSH组 131 53(21.9) 40(30.5) 24(50.0) 6(15.0) 7(17.5) 4(2.8)
χ2值   0.060 2.421 4.607 0.003 0.047 0.579
P值   0.806 0.120 0.033 0.954 0.829 0.448
[1]
Al-Inany H, Aboulghar M, Mansour R, et al. Meta-analysis of recombinant versus urinary-derived FSH: an update[J]. Hum Reprod, 2003, 18(2):305-313.
[2]
蒋元华，段金良．丽申宝与果纳芬在IVF-ET长方案的临床比较[J]．中国性科学，2013, 22(1):29-31.
[3]
张娟，方小玲，谭小军，等. 果那芬和丽申宝在超促排卵治疗中的疗效比较[J]．生殖医学杂志，2013, 22(1):62-64.
[4]
Fulghesu AM, Apa R, Belosi C, et al. Recombinant versus urinary follicle-stimulating hormone in the low-dose regimen in anovulatory patients with polycystic ovary syndrome: a safer and more effective treatment[J]. Horm Res, 2001, 55(5):224-228.
[5]
Streda R, Koryntová D, Mardesic T, et al. Clinical effects of recombinant versus urinary gonadotropins in ovulation induction [J]. Ceska Gynekol, 2011, 76(2):108-113.
[6]
Hugues JN, Bry-Gauillard H, Bständig B, et al. Comparison of recombinant and urinary follicle-stimulating hormone preparations in short-term gonadotropin releasing hormone agonist protocol for in vitro fertilization-embryotransfer [J]. J Assist Reprod Genet, 2001, 18(4):191-196.
[7]
Loumaye E, Dreano M, Galazka, et al. Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility [J]. Hum Reprod Update, 1998, 4:862-881.
[8]
Daya S, Ledger W, Auray JP, et al. Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK [J]. Hum Reprod, 2001, 16(12):2563-2569.
[9]
Balasch J, Barri PN. Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective [J]. J Assist Reprod Genet, 2001, 18(2):45-55.
[10]
Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles[J]. Hum Reprod, 2011, 26(7):1768-1774.
[11]
Stoop D, Ermini B, Polyzos NP, et al. Reproductive potential of a metaphase Ⅱ oocyte retrieved after ovarian stimulation: an analysis of 23 354 ICSI cycles [J]. Hum Reprod, 2012, 27(7):2030-2035.
[12]
Macklon NS, Fauser BC. Mild stimulation in in vitro fertilization [J]. Ann NY Acad Sci, 2003, 997:105-111.
[13]
Pellicer A, Ballester MJ. Aetiological factors involved in the low response to gonadotrophins in infertile women with normal basal serum follicle stimulating hormone levels [J]. Hum Reprod, 1994, 9(5):806-811.
[14]
Liu X, Hao C, Wang J. Efficacy of highly purified urinary FSH versus recombinant FSH in chinese women over 37 years undergoing assisted reproductive techniques [J]. Int J Fertil Steril, 2015, 8(4):385-392.
[15]
Mochtar MH, Van der Veen, Ziech M, et al. Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles [J]. Cochrane Database Syst Rev, 2007, 18(2):CD005070-CD005070.
[16]
Matorras R, Prieto B, Exposito A, et al. Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study [J]. Reprod Biomed Online, 2009, 19(6):879-887.
[17]
Hillier SG. Paracrine support of ovarian stimulation [J]. Mol Hum Reprod, 2009, 15(12):843-850.
[1] 李欣, 魏艺, 张娟, 张娟娟, 凌秀凤, 赵纯, 张媔秋. 高龄女性冻胚移植周期临床妊娠结局的影响因素分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 276-283.
[2] 高青卓, 康宜凡, 王治鸿. 体外受精周期中单原核胚胎的临床研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 260-265.
[3] 魏丽坤, 张旭红, 罗营, 薛凤霞, 王颖梅, 宋学茹, 田丽娜, 张艳芳, 王艳霞, 田文艳. 卵巢子宫内膜异位囊肿发生恶变并发盆腔脓肿1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 696-702.
[4] 王丽, 王月莺, 周芬, 郭宇堃, 魏丽娜. 促性腺激素释放激素拮抗剂对子宫内膜容受性影响的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 629-635.
[5] 顾娟, 孙擎擎, 胡方方, 曹义娟, 祁玉娟. 子宫内膜容受性检测改善胚胎反复种植失败患者妊娠结局的临床应用[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 582-587.
[6] 王丁然, 迟洪滨. 自身免疫甲状腺炎对子宫内膜异位症患者胚胎移植结局的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(06): 682-688.
[7] 汪文雁, 郑剑兰, 朱丽慈. 体外受精-胚胎移植术后妊娠患者孕产期风险的临床研究[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 220-226.
[8] 胡淼, 杜丽丽, 张丽姿, 林琳, 张瑜亮, 古士锋, 古仲嘉, 赖思莹, 梁景英, 刘雨, 黄敏珊, 黄媛媛, 黄晴晴, 罗世君, 陈敦金. 体外受精/卵胞浆内单精子注射受孕患者胎盘植入分级及围产结局的研究[J/OL]. 中华产科急救电子杂志, 2024, 13(03): 183-189.
[9] 洪凡, 陈敦金, 傅洋, 梁新月, 吴毅, 王晓怡. 体外受精-胚胎移植妊娠合并前置胎盘临床研究[J/OL]. 中华产科急救电子杂志, 2024, 13(03): 176-182.
[10] 刘文易, 高晓彤, 汤景, 麦卓瑶, 祝丽琼, 陈慧. 体外受精-胚胎移植妊娠合并绒毛膜下血肿患者妊娠结局的临床研究[J/OL]. 中华产科急救电子杂志, 2024, 13(02): 93-99.
[11] 张舒沁, 赵扬玉. 体外受精-胚胎移植与妊娠期高血压疾病[J/OL]. 中华产科急救电子杂志, 2024, 13(02): 79-83.
[12] 张慧婷, 冯玲. 体外受精-胚胎移植技术与早产[J/OL]. 中华产科急救电子杂志, 2024, 13(02): 73-78.
[13] 卫星, 孙路明. 辅助生殖技术与胎儿生长障碍[J/OL]. 中华产科急救电子杂志, 2024, 13(02): 88-92.
[14] 李婷, 滕银成. 体外受精-胚胎移植与前置胎盘[J/OL]. 中华产科急救电子杂志, 2024, 13(02): 84-87.
[15] 王山云, 张红春, 曾建峰. 切脉针刺辅助治疗体外受精-胚胎移植案例分析[J/OL]. 中华针灸电子杂志, 2024, 13(01): 24-24.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号